Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MDR-103 for Induction of Tolerance in Past Kidney Transplant Recipients
NCT03606746Phase 2Withdrawn
- Sponsor
- Medeor Therapeutics
- Start
- Dec 2024
- Primary completion
- Aug 2025
- Modality
- Stem Cell Therapies
01
Overview
A Phase 2 trial of MDR-103 in kidney transplant rejection, sponsored by Medeor Therapeutics. Planned start Dec 2024; status: withdrawn.
02
Drugs
MDR-103
03
Conditions
kidney transplant rejection
Beyond the preview
Go deeper on NCT03606746.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03606746.